胶质瘤干细胞与治疗恶性胶质瘤的免疫疗法。
Glioma stem cells and immunotherapy for the treatment of malignant gliomas.
作者信息
Toda Masahiro
机构信息
Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
出版信息
ISRN Oncol. 2013 May 15;2013:673793. doi: 10.1155/2013/673793. Print 2013.
Abstract
Stem cell research has led to the discovery of glioma stem cells (GSCs), and because these cells are resistant to chemotherapy and radiotherapy, analysis of their properties has been rapidly pursued for targeted treatment of malignant glioma. Recent studies have also revealed complex crosstalk between GSCs and their specialized environment (niche). Therefore, targeting not only GSCs but also their niche may be a principle for novel therapies of malignant glioma. One possible novel strategy for targeting GSCs and their niches is immunotherapy with different antitumor mechanism(s) from those of conventional therapy. Recent clinical studies of immunotherapy using peptide vaccines and antibodies have shown promising results. This review describes the recent findings related to GSCs and their niches, as well as immunotherapies for glioma, followed by discussion of immunotherapies that target GSCs for the treatment of malignant glioma.
摘要
干细胞研究促使了胶质瘤干细胞（GSCs）的发现，由于这些细胞对化疗和放疗具有抗性，因此人们迅速对其特性进行分析，以实现恶性胶质瘤的靶向治疗。最近的研究还揭示了胶质瘤干细胞与其特殊微环境（生态位）之间复杂的相互作用。因此，不仅靶向胶质瘤干细胞，而且靶向其生态位可能是恶性胶质瘤新疗法的一个原则。一种针对胶质瘤干细胞及其生态位的可能新策略是采用与传统疗法不同抗肿瘤机制的免疫疗法。最近使用肽疫苗和抗体进行免疫治疗的临床研究已显示出有前景的结果。本综述描述了与胶质瘤干细胞及其生态位相关的最新发现，以及胶质瘤的免疫疗法，随后讨论了针对恶性胶质瘤治疗靶向胶质瘤干细胞的免疫疗法。
相似文献
1
Glioma stem cells and immunotherapy for the treatment of malignant gliomas.胶质瘤干细胞与治疗恶性胶质瘤的免疫疗法。
ISRN Oncol. 2013 May 15;2013:673793. doi: 10.1155/2013/673793. Print 2013.
2
The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment.癌症干细胞生态位：胶质瘤干细胞与其微环境之间的相互作用
Biochim Biophys Acta. 2013 Feb;1830(2):2496-508. doi: 10.1016/j.bbagen.2012.10.008. Epub 2012 Oct 16.
3
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.硼替佐米抑制蛋白酶体诱导 GBM 干细胞样细胞和替莫唑胺耐药神经胶质瘤细胞系的细胞死亡，但刺激 GBM 干细胞样细胞的 VEGF 产生和血管生成。
J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.
4
Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.鉴定胶质瘤干细胞中表达的 SOX6 所诱导的 HLA-A2 和 A24 限制性 T 细胞表位，用于免疫治疗。
Int J Cancer. 2010 Feb 15;126(4):919-29. doi: 10.1002/ijc.24851.
5
Targeting glioma stem cells: enough to terminate gliomagenesis?靶向神经胶质瘤干细胞：足以终止神经胶质瘤发生？
Chin Med J (Engl). 2011 Sep;124(17):2756-63.
6
Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.促进胶质瘤干细胞向少突胶质细胞方向分化：喹硫平用于治疗恶性胶质瘤的新用途。
Oncotarget. 2017 Jun 6;8(23):37511-37524. doi: 10.18632/oncotarget.16400.
7
The roles of hypoxia-inducible factors in regulating neural stem cells migration to glioma stem cells and determinating their fates.缺氧诱导因子在调节神经干细胞向神经胶质瘤干细胞迁移及其命运中的作用。
Neurochem Res. 2012 Dec;37(12):2659-66. doi: 10.1007/s11064-012-0879-x. Epub 2012 Sep 19.
8
The hypoxic peri-arteriolar glioma stem cell niche, an integrated concept of five types of niches in human glioblastoma.缺氧的血管周围胶质瘤干细胞龛，人类脑胶质瘤中五种龛的综合概念。
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):346-354. doi: 10.1016/j.bbcan.2018.04.008. Epub 2018 Apr 21.
9
Interferon-beta inhibits human glioma stem cell growth by modulating immune response and cell cycle related signaling pathways.干扰素-β通过调节免疫反应和细胞周期相关信号通路来抑制人胶质瘤干细胞的生长。
Cell Regen. 2022 Jul 2;11(1):23. doi: 10.1186/s13619-022-00123-w.
10
Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells.增强体外侵袭和体内 CD133+脑肿瘤干细胞的分布模式。
Chin Med J (Engl). 2011 Sep;124(17):2599-604.
引用本文的文献
1
The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas.细胞外囊泡在胶质母细胞瘤获得治疗抗性中的作用。
Cancer Drug Resist. 2021 Mar 19;4(1):1-16. doi: 10.20517/cdr.2020.61. eCollection 2021.
2
Current Immunotherapeutic Approaches for Malignant Gliomas.恶性胶质瘤的当前免疫治疗方法
Brain Tumor Res Treat. 2022 Jan;10(1):1-11. doi: 10.14791/btrt.2022.10.e25.
3
Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas.利用谷氨酰胺氨甲酰转移酶，恶性脑胶质瘤代谢重编程的核心。
Biomolecules. 2020 Sep 26;10(10):1370. doi: 10.3390/biom10101370.
4
Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening.通过细胞生长速率筛选来扩增基因不同的患者来源的胶质瘤干细胞的球形形成培养
Cancers (Basel). 2020 Feb 27;12(3):549. doi: 10.3390/cancers12030549.
5
The Autophagy Status of Cancer Stem Cells in Gliobastoma Multiforme: From Cancer Promotion to Therapeutic Strategies.胶质母细胞瘤中肿瘤干细胞的自噬状态：从癌症促进到治疗策略。
Int J Mol Sci. 2019 Aug 5;20(15):3824. doi: 10.3390/ijms20153824.
6
Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.利用自然杀伤细胞衍生的外泌体在小鼠模型中靶向和治疗神经胶质瘤。
Front Immunol. 2018 Apr 23;9:824. doi: 10.3389/fimmu.2018.00824. eCollection 2018.
7
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies.纳米医学在癌症干细胞靶向治疗中的意义及未来展望
Front Mol Biosci. 2017 Jul 21;4:52. doi: 10.3389/fmolb.2017.00052. eCollection 2017.
8
Comparison of Allogeneic and Syngeneic Rat Glioma Models by Using MRI and Histopathologic Evaluation.使用磁共振成像（MRI）和组织病理学评估比较同种异体和同基因大鼠胶质瘤模型
Comp Med. 2017 Mar 1;67(2):147-156.
9
Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets.胶质瘤干细胞及其微环境：具有挑战性的治疗靶点来源
Stem Cells Int. 2016;2016:5728438. doi: 10.1155/2016/5728438. Epub 2016 Feb 10.
10
Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.自然杀伤（NK）细胞可抑制胶质母细胞瘤细胞的全身转移，并对脑部的胶质母细胞瘤具有治疗作用。
BMC Cancer. 2015 Dec 24;15:1011. doi: 10.1186/s12885-015-2034-y.
本文引用的文献
1
The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment.癌症干细胞生态位：胶质瘤干细胞与其微环境之间的相互作用
Biochim Biophys Acta. 2013 Feb;1830(2):2496-508. doi: 10.1016/j.bbagen.2012.10.008. Epub 2012 Oct 16.
2
Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting.胶质母细胞瘤癌症干细胞：微环境的作用和治疗靶点。
Biochem Pharmacol. 2013 Mar 1;85(5):612-622. doi: 10.1016/j.bcp.2012.10.001. Epub 2012 Oct 11.
3
Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.OTS11101 是一种针对实体瘤血管内皮生长因子受体 1 的抗血管生成疫苗的 I 期临床试验。
Cancer Sci. 2013 Jan;104(1):98-104. doi: 10.1111/cas.12034. Epub 2012 Nov 8.
4
Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report.晚期结肠癌对肽疫苗治疗的显著临床反应：一例病例报告
Tokai J Exp Clin Med. 2012 Jul 20;37(2):57-61.
5
Glioma stem cell research for the development of immunotherapy.胶质瘤干细胞研究用于免疫疗法的开发。
Adv Exp Med Biol. 2012;746:216-25. doi: 10.1007/978-1-4614-3146-6_17.
6
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.自体树突状细胞瘤内免疫疗法与新诊断胶质母细胞瘤标准治疗的整合：HGG-2006 期 I/II 试验结果。
Cancer Immunol Immunother. 2012 Nov;61(11):2033-44. doi: 10.1007/s00262-012-1261-1. Epub 2012 Apr 22.
7
Malignant glioma: lessons from genomics, mouse models, and stem cells.恶性神经胶质瘤：从基因组学、小鼠模型和干细胞中得到的启示。
Cell. 2012 Mar 30;149(1):36-47. doi: 10.1016/j.cell.2012.03.009.
8
Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele.针对 HLA-A*24/A*02 等位基因的复发性恶性脑胶质瘤患者，白细胞介素 13 受体 α2 链肽脉冲树突状细胞疫苗接种。
Cytotherapy. 2012 Jul;14(6):733-42. doi: 10.3109/14653249.2012.666633. Epub 2012 Mar 16.
9
Immunotherapy targeting glioma stem cells--insights and perspectives.针对神经胶质瘤干细胞的免疫疗法——见解与展望。
Expert Opin Biol Ther. 2012 Feb;12(2):165-78. doi: 10.1517/14712598.2012.648180. Epub 2011 Dec 26.
10
Eyes wide open: a critical review of sphere-formation as an assay for stem cells.眼睛睁得大大的：球体形成作为干细胞检测方法的批判性评价。
Cell Stem Cell. 2011 May 6;8(5):486-98. doi: 10.1016/j.stem.2011.04.007.
Zotero 插件